Switch to:
Also traded in: Austria, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 4.67
VRTX's Cash-to-Debt is ranked lower than
62% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. VRTX: 4.67 )
Ranked among companies with meaningful Cash-to-Debt only.
VRTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.66  Med: 2.47 Max: 26.61
Current: 4.67
0.66
26.61
Equity-to-Asset 0.62
VRTX's Equity-to-Asset is ranked lower than
58% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. VRTX: 0.62 )
Ranked among companies with meaningful Equity-to-Asset only.
VRTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.02  Med: 0.51 Max: 0.95
Current: 0.62
-0.02
0.95
Debt-to-Equity 0.22
VRTX's Debt-to-Equity is ranked higher than
56% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. VRTX: 0.22 )
Ranked among companies with meaningful Debt-to-Equity only.
VRTX' s Debt-to-Equity Range Over the Past 10 Years
Min: -39.45  Med: 0.39 Max: 9.45
Current: 0.22
-39.45
9.45
Debt-to-EBITDA 2.47
VRTX's Debt-to-EBITDA is ranked lower than
59% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. VRTX: 2.47 )
Ranked among companies with meaningful Debt-to-EBITDA only.
VRTX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.01  Med: -0.47 Max: 11.14
Current: 2.47
-2.01
11.14
Interest Coverage 7.55
VRTX's Interest Coverage is ranked lower than
88% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VRTX: 7.55 )
Ranked among companies with meaningful Interest Coverage only.
VRTX' s Interest Coverage Range Over the Past 10 Years
Min: 0.14  Med: 4.56 Max: 7.55
Current: 7.55
0.14
7.55
Piotroski F-Score: 6
Altman Z-Score: 16.56
Beneish M-Score: -2.69
WACC vs ROIC
13.52%
115.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 13.63
VRTX's Operating Margin % is ranked higher than
84% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. VRTX: 13.63 )
Ranked among companies with meaningful Operating Margin % only.
VRTX' s Operating Margin % Range Over the Past 10 Years
Min: -581.79  Med: -28.97 Max: 15.78
Current: 13.63
-581.79
15.78
Net Margin % 15.84
VRTX's Net Margin % is ranked higher than
87% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. VRTX: 15.84 )
Ranked among companies with meaningful Net Margin % only.
VRTX' s Net Margin % Range Over the Past 10 Years
Min: -630.27  Med: -45.31 Max: 15.84
Current: 15.84
-630.27
15.84
ROE % 19.62
VRTX's ROE % is ranked higher than
93% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. VRTX: 19.62 )
Ranked among companies with meaningful ROE % only.
VRTX' s ROE % Range Over the Past 10 Years
Min: -180.27  Med: -46.5 Max: 19.62
Current: 19.62
-180.27
19.62
ROA % 11.34
VRTX's ROA % is ranked higher than
92% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. VRTX: 11.34 )
Ranked among companies with meaningful ROA % only.
VRTX' s ROA % Range Over the Past 10 Years
Min: -58.14  Med: -20.28 Max: 11.34
Current: 11.34
-58.14
11.34
ROC (Joel Greenblatt) % 22.25
VRTX's ROC (Joel Greenblatt) % is ranked higher than
87% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. VRTX: 22.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VRTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1092.55  Med: -80.37 Max: 95.5
Current: 22.25
-1092.55
95.5
3-Year Revenue Growth Rate 58.50
VRTX's 3-Year Revenue Growth Rate is ranked higher than
90% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. VRTX: 58.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
VRTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -32.5  Med: 13 Max: 129.4
Current: 58.5
-32.5
129.4
GuruFocus has detected 2 Warning Signs with Vertex Pharmaceuticals Inc VRTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VRTX's 30-Y Financials

Financials (Next Earnings Date: 2018-10-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

VRTX Guru Trades in Q3 2017

Louis Moore Bacon 25,000 sh (New)
Caxton Associates 2,000 sh (New)
Ron Baron 29,783 sh (New)
Steven Cohen 909,230 sh (+8061.12%)
Jim Simons 1,368,020 sh (+6204.24%)
David Carlson 230,000 sh (unchged)
Ray Dalio Sold Out
Pioneer Investments 1,271,676 sh (-4.15%)
Ken Fisher 4,984 sh (-16.18%)
Vanguard Health Care Fund 9,658,658 sh (-16.93%)
Joel Greenblatt 110,500 sh (-39.46%)
Manning & Napier Advisors, Inc 885,868 sh (-45.69%)
Eaton Vance Worldwide Health Sciences Fund 154,789 sh (-14.36%)
» More
Q4 2017

VRTX Guru Trades in Q4 2017

Paul Tudor Jones 10,416 sh (New)
Jim Simons 2,847,917 sh (+108.18%)
Ron Baron 43,371 sh (+45.62%)
Ken Fisher 5,089 sh (+2.11%)
Pioneer Investments 1,288,046 sh (+1.29%)
David Carlson 230,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 154,789 sh (unchged)
Caxton Associates Sold Out
Louis Moore Bacon Sold Out
Vanguard Health Care Fund 9,003,258 sh (-6.79%)
Steven Cohen 709,817 sh (-21.93%)
Joel Greenblatt 14,984 sh (-86.44%)
» More
Q1 2018

VRTX Guru Trades in Q1 2018

Ron Baron 62,137 sh (+43.27%)
Jim Simons 2,850,917 sh (+0.11%)
David Carlson 230,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 154,789 sh (unchged)
Ken Fisher Sold Out
Joel Greenblatt 14,974 sh (-0.07%)
Pioneer Investments 1,274,114 sh (-1.08%)
Vanguard Health Care Fund 7,942,322 sh (-11.78%)
Paul Tudor Jones 2,431 sh (-76.66%)
Steven Cohen 30,000 sh (-95.77%)
» More
Q2 2018

VRTX Guru Trades in Q2 2018

Ray Dalio 15,509 sh (New)
Paul Tudor Jones 17,588 sh (+623.49%)
Ron Baron 83,752 sh (+34.79%)
David Carlson 270,000 sh (+17.39%)
Vanguard Health Care Fund 7,354,517 sh (-7.40%)
Pioneer Investments 195,756 sh (-84.64%)
Eaton Vance Worldwide Health Sciences Fund 144,257 sh (-6.80%)
» More
» Details

Insider Trades

Latest Guru Trades with VRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-06-30 Reduce -7.40%0.21%$145.72 - $169.96 $ 172.2511%7,354,517
Ron Baron 2018-06-30 Add 34.79%0.02%$145.72 - $169.96 $ 172.2511%83,752
Joel Greenblatt 2018-06-30 Sold Out 0.03%$145.72 - $169.96 $ 172.2511%0
Vanguard Health Care Fund 2018-03-31 Reduce -11.78%0.35%$151.6 - $177.13 $ 172.255%7,942,322
Ron Baron 2018-03-31 Add 43.27%0.02%$151.6 - $177.13 $ 172.255%62,137
Joel Greenblatt 2018-03-31 Reduce -0.07%$151.6 - $177.13 $ 172.255%14,974
Ken Fisher 2018-03-31 Sold Out $151.6 - $177.13 $ 172.255%0
Vanguard Health Care Fund 2017-12-31 Reduce -6.79%0.21%$137.28 - $155.55 $ 172.2516%9,003,258
Ron Baron 2017-12-31 Add 45.62%0.01%$137.28 - $155.55 $ 172.2516%43,371
Joel Greenblatt 2017-12-31 Reduce -86.44%0.22%$137.28 - $155.55 $ 172.2516%14,984
Ken Fisher 2017-12-31 Add 2.11%$137.28 - $155.55 $ 172.2516%5,089
Vanguard Health Care Fund 2017-09-30 Reduce -16.93%0.55%$128.23 - $166.11 $ 172.2515%9,658,658
Joel Greenblatt 2017-09-30 Reduce -39.46%0.13%$128.23 - $166.11 $ 172.2515%110,500
Ron Baron 2017-09-30 New Buy0.02%$128.23 - $166.11 $ 172.2515%29,783
Ken Fisher 2017-09-30 Reduce -16.18%$128.23 - $166.11 $ 172.2515%4,984
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:REGN, XKRX:068270, XKRX:207940, LSE:SHP, NAS:ALXN, NAS:BIIB, ASX:CSL, HKSE:01177, XMCE:GRF.P, NAS:BMRN, XBRU:UCB, NAS:NKTR, OCSE:NZYM B, NAS:INCY, OCSE:GEN, NAS:BIVV, HKSE:02269, NAS:CELG, NAS:JUNO, NAS:ALNY » details
Traded in other countries:VRTX.Austria, VX1.Germany, VRTX.Mexico, VRTX.Switzerland, 0QZU.UK,
Headquarter Location:USA
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its products include SYMDEKO, ORKAMBI, and KALYDECO.

Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco and Orkambi for cystic fibrosis, and the company also has several mid- and late-stage products targeting this market. Vertex successfully developed and commercialized two HIV protease inhibitors, which were outlicensed to GlaxoSmithKline. Vertex's pipeline also includes therapies for the treatment of cancer, pain, inflammatory diseases, and influenza.

Top Ranked Articles about Vertex Pharmaceuticals Inc

Factors of Influence in 2018, Key Indicators and Opportunity within Immunomedics, Vertex Pharmaceuticals, Ralph Lauren, Alliant Energy, TreeHouse Foods, and Lincoln National — New Research Emphasizes Economic Growth
Wall Street Opens Red Monday Xerium Technologies more than doubles on acquisition news
The U.S. stock market fell today, with the Dow Jones down more than 200 points. According to the Wall Street Journal, President Trump will restrict Chinese companies' investment in the tech sector, but the news will be announced later in the week. Read more...
CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease
5 Health Care Stocks Gurus Are Buying Akebia Therapeutics, Macrogenics on the list
According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus. Read more...
Factors of Influence in 2018, Key Indicators and Opportunity within American Homes 4 Rent, Discovery Communications, Vertex Pharmaceuticals, The New York Times, Palatin Technologies, and E*TRADE Financial — New Research Emphasizes Economic Growth
Drug Prices Too High? Don’t Blame Rebates. Blame the FDA Approval Process Both biotech and pharma may soon come under a pricing attack, and it could endanger future research initiatives and the flow of new drugs to market
It looks like regulators are once again trying to solve a problem caused by overregulation with more regulation. The news does not look good for drug companies anywhere from privately funded startups all the way to Big Pharma. Read more...
Vanguard Health Care Reduces Abbott, Bristol-Myers Positions Fund's largest sales of the 1st quarter
The Vanguard Health Care Fund (Trades, Portfolio) sold shares of the following stocks in the first quarter. Read more...
Spring Forecast: Stocks to Buy With Your Tax Refund Investing your tax refund: best buys for spring
The stock market has been off to a rough start in 2018, with many speculating about a potential crash or a bear market. On closer inspection, though, it seems clear that the market is simply undergoing a typical correction in the wake of an earlier bull market. This is a natural trend and part of stabilizing the market for further investment – and makes it safe for investors to start wondering what stocks are good contenders for spring investments. Read more...
Steven Cohen Takes Stake in Biotech Company Agenus Guru expands position in health care space
Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed this week he established a 6.13% stake in Agenus Inc. (NASDAQ:AGEN) on Feb. 21. Read more...
Wall Street Mixed on Thursday Ralph Lauren also disappoints on North America sales
U.S. stocks advanced in pre-market trading on Thursday ahead of positive macroeconomic data that showed that productivity increased 1.2% in 2017, compared to a 0.1% drop last year. However, they then entered into red zone. Read more...

Ratios

vs
industry
vs
history
PE Ratio 107.65
VRTX's PE Ratio is ranked lower than
88% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. VRTX: 107.65 )
Ranked among companies with meaningful PE Ratio only.
VRTX' s PE Ratio Range Over the Past 10 Years
Min: 25.82  Med: 137.84 Max: 560.57
Current: 107.65
25.82
560.57
Forward PE Ratio 54.35
VRTX's Forward PE Ratio is ranked lower than
75% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 28.41 vs. VRTX: 54.35 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 107.65
VRTX's PE Ratio without NRI is ranked lower than
87% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. VRTX: 107.65 )
Ranked among companies with meaningful PE Ratio without NRI only.
VRTX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 25.82  Med: 148.55 Max: 560.57
Current: 107.65
25.82
560.57
Price-to-Owner-Earnings 118.55
VRTX's Price-to-Owner-Earnings is ranked lower than
88% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 34.35 vs. VRTX: 118.55 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
VRTX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 20.93  Med: 160.73 Max: 546.26
Current: 118.55
20.93
546.26
PB Ratio 16.35
VRTX's PB Ratio is ranked lower than
90% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. VRTX: 16.35 )
Ranked among companies with meaningful PB Ratio only.
VRTX' s PB Ratio Range Over the Past 10 Years
Min: 5.78  Med: 15.57 Max: 37.6
Current: 16.35
5.78
37.6
PS Ratio 16.83
VRTX's PS Ratio is ranked lower than
58% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. VRTX: 16.83 )
Ranked among companies with meaningful PS Ratio only.
VRTX' s PS Ratio Range Over the Past 10 Years
Min: 4.47  Med: 17.24 Max: 79.6
Current: 16.83
4.47
79.6
Price-to-Free-Cash-Flow 65.21
VRTX's Price-to-Free-Cash-Flow is ranked lower than
68% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. VRTX: 65.21 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
VRTX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.84  Med: 67.94 Max: 1552.81
Current: 65.21
11.84
1552.81
Price-to-Operating-Cash-Flow 45.47
VRTX's Price-to-Operating-Cash-Flow is ranked lower than
68% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. VRTX: 45.47 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
VRTX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.94  Med: 49.42 Max: 242.49
Current: 45.47
11.94
242.49
EV-to-EBIT 240.88
VRTX's EV-to-EBIT is ranked lower than
95% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. VRTX: 240.88 )
Ranked among companies with meaningful EV-to-EBIT only.
VRTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -16203  Med: -10.5 Max: 1510.2
Current: 240.88
-16203
1510.2
EV-to-EBITDA 174.57
VRTX's EV-to-EBITDA is ranked lower than
94% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. VRTX: 174.57 )
Ranked among companies with meaningful EV-to-EBITDA only.
VRTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1137.1  Med: -10.5 Max: 2184.4
Current: 174.57
-1137.1
2184.4
EV-to-Revenue 15.96
VRTX's EV-to-Revenue is ranked lower than
53% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. VRTX: 15.96 )
Ranked among companies with meaningful EV-to-Revenue only.
VRTX' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.2  Med: 16.5 Max: 76.5
Current: 15.96
4.2
76.5
Current Ratio 3.67
VRTX's Current Ratio is ranked lower than
58% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. VRTX: 3.67 )
Ranked among companies with meaningful Current Ratio only.
VRTX' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 4.51 Max: 30.95
Current: 3.67
1.14
30.95
Quick Ratio 3.55
VRTX's Quick Ratio is ranked lower than
56% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. VRTX: 3.55 )
Ranked among companies with meaningful Quick Ratio only.
VRTX' s Quick Ratio Range Over the Past 10 Years
Min: 1.14  Med: 4.51 Max: 30.95
Current: 3.55
1.14
30.95
Days Inventory 117.23
VRTX's Days Inventory is ranked higher than
54% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. VRTX: 117.23 )
Ranked among companies with meaningful Days Inventory only.
VRTX' s Days Inventory Range Over the Past 10 Years
Min: 62.49  Med: 125.66 Max: 254.87
Current: 117.23
62.49
254.87
Days Sales Outstanding 54.75
VRTX's Days Sales Outstanding is ranked higher than
60% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. VRTX: 54.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
VRTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.75  Med: 42.11 Max: 61.46
Current: 54.75
25.75
61.46
Days Payable 91.03
VRTX's Days Payable is ranked higher than
60% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. VRTX: 91.03 )
Ranked among companies with meaningful Days Payable only.
VRTX' s Days Payable Range Over the Past 10 Years
Min: 91.03  Med: 279.06 Max: 1204.41
Current: 91.03
91.03
1204.41

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.60
VRTX's 3-Year Average Share Buyback Ratio is ranked higher than
88% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. VRTX: -1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VRTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.2  Med: -12.3 Max: -1.6
Current: -1.6
-23.2
-1.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 38.28
VRTX's Price-to-Net-Cash is ranked lower than
88% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. VRTX: 38.28 )
Ranked among companies with meaningful Price-to-Net-Cash only.
VRTX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.55  Med: 20.42 Max: 2359.4
Current: 38.28
3.55
2359.4
Price-to-Net-Current-Asset-Value 24.57
VRTX's Price-to-Net-Current-Asset-Value is ranked lower than
88% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. VRTX: 24.57 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VRTX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.16  Med: 12.94 Max: 12583
Current: 24.57
2.16
12583
Price-to-Tangible-Book 16.84
VRTX's Price-to-Tangible-Book is ranked lower than
85% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. VRTX: 16.84 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VRTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.88  Med: 9.08 Max: 120.7
Current: 16.84
1.88
120.7
Price-to-Intrinsic-Value-Projected-FCF 16.37
VRTX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
93% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. VRTX: 16.37 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
VRTX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 16.16  Med: 31.7 Max: 819.67
Current: 16.37
16.16
819.67
Price-to-Median-PS-Value 0.98
VRTX's Price-to-Median-PS-Value is ranked lower than
56% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. VRTX: 0.98 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VRTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.29  Med: 1.09 Max: 4.34
Current: 0.98
0.29
4.34
Price-to-Graham-Number 8.98
VRTX's Price-to-Graham-Number is ranked lower than
93% of the 200 Companies
in the Global Biotechnology industry.

( Industry Median: 2.27 vs. VRTX: 8.98 )
Ranked among companies with meaningful Price-to-Graham-Number only.
VRTX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.35  Med: 11.6 Max: 40.01
Current: 8.98
2.35
40.01
Earnings Yield (Greenblatt) % 0.41
VRTX's Earnings Yield (Greenblatt) % is ranked higher than
77% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. VRTX: 0.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VRTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -26.5  Med: -2.7 Max: 5.2
Current: 0.41
-26.5
5.2

More Statistics

Revenue (TTM) (Mil) $2,622.76
EPS (TTM) $ 1.60
Beta1.86
Volatility19.71%
52-Week Range $136.50 - 183.39
Shares Outstanding (Mil)255.56

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 2,928 3,504 4,304
EBIT (Mil $) 736 1,154 1,849
EBITDA (Mil $) 921 1,302 1,981
EPS ($) 2.43 3.51 5.70
EPS without NRI ($) 2.43 3.51 5.70
EPS Growth Rate
(Future 3Y To 5Y Estimate)
64.97%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}